Close

Drug Research

Stevanato Group launches AI platform to further enhance detection performance of its visual inspection machines

Stevanato Group, a leading global provider of integrated containment and delivery solutions to the biopharmaceutical and life sciences industries, has launched an Artificial Intelligence platform, based on Deep Learning (DL) models, that leverages the benefits of human-like decision-making in...

Merck and Transylvanian Institute of Neuroscience Cooperate on Brain-Inspired Artificial Intelligence

Merck, a leading science and technology company,  announced a three-year collaboration with the Transylvanian Institute of Neuroscience (TINS), based in Cluj-Napoca, Romania. The primary focus of this collaboration between the private non-profit research institute TINS and the Artificial Intelligence...

Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands

Sanofi has entered into an agreement with Janssen Pharmaceutical NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson, under which Sanofi will support manufacturing of Janssen´s COVID-19 vaccine in order to address the...

Lilly and Rigel collaborate to develop RIPK1 inhibitors for potential treatment of immunological and neurodegenerative diseases

Eli Lilly and Company and Rigel Pharmaceuticals, Inc. announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. Pursuant...

AstraZeneca, IDT To Ramp Up COVID-19 Vaccine Manufacturing In Europe

Following the European Medicines Agency (EMA) approval, millions of AstraZeneca vaccines began shipping on 5 February as part of the initial 17m doses that are due to be delivered over the next weeks, with more planned in March. AstraZeneca and...

Catalent Signs Development and Manufacturing Agreement with Trizell for Macrophage-based Advanced Cell Therapy

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it had signed an agreement with Trizell GmbH, to support the manufacturing of...

Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab

Avid Bioservices, Inc. and Humanigen, Inc. announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab™, Humanigen’s therapeutic candidate in development for COVID-19. Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read